Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S282700
Reexamination Certificate
active
07872030
ABSTRACT:
(R/S)-(−/+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof and/or (S)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof are used for the manufacture of a medicament for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders.
REFERENCES:
patent: 4438119 (1984-03-01), Allen et al.
patent: 4981695 (1991-01-01), Appelgren et al.
patent: 5137901 (1992-08-01), Junge et al.
patent: 5141930 (1992-08-01), Nakao et al.
patent: 5314888 (1994-05-01), Dodman et al.
patent: 5318988 (1994-06-01), Schohe-Loop et al.
patent: 5468882 (1995-11-01), Schohe-Loop et al.
patent: 5502080 (1996-03-01), Hitzig
patent: 5541199 (1996-07-01), Mewshaw
patent: 5670667 (1997-09-01), Mewshaw
patent: 5756521 (1998-05-01), Mewshaw
patent: 5762960 (1998-06-01), Dodman
patent: 5767132 (1998-06-01), Bottcher et al.
patent: 5935973 (1999-08-01), Birch et al.
patent: 6114334 (2000-09-01), Kerrigan et al.
patent: 6214829 (2001-04-01), Feenstra et al.
patent: 6235774 (2001-05-01), Fahrig et al.
patent: 6242456 (2001-06-01), Dodman et al.
patent: 2003/0181486 (2003-09-01), Bartoszyk et al.
patent: 2364685 (1975-07-01), None
patent: 4135474 (1993-04-01), None
patent: 4226527 (1994-02-01), None
patent: 196 48 384 (1998-05-01), None
patent: 0145067 (1985-06-01), None
patent: 0465254 (1992-01-01), None
patent: 0707007 (1996-04-01), None
patent: 0900792 (1999-03-01), None
patent: WO 93/17670 (1993-09-01), None
patent: WO 9317017 (1993-09-01), None
patent: WO 9418196 (1994-08-01), None
patent: WO 9533729 (1995-12-01), None
patent: WO 9703071 (1997-01-01), None
patent: WO 9945906 (1999-09-01), None
patent: WO 9955672 (1999-11-01), None
patent: WO 0029397 (2000-05-01), None
PubMed Id: 7857027, 1994.
Church, Andrew J. and Giovannoni, Gavin “Poststreptococcal movement disorders” in Neuroimmunology in Clinical Practice Eds. Bernadette Kalman and Thomas H. Brannagan III Blackwell: 2008 Chapter 21, pp. 240-250.
Fodstad et. al. “Intractable singultus: a diagnostic and therapeutic challenge” British Journal of Neurosurgery 1993, 7, 255-262.
Kalviainen, R. “Clinical picture of EPM1-Unverricht-Lundborg disease” Epilepsia, 49(4):549-556, 2008.
Adam, Octavian R. “Symptomatic Treatment of Huntington Disease” Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Apr. 2008, vol. 5, 181-197.
Tamaki et. al. “Effects of 8-OH-DPAT, a 5-HT1A Receptor Agonist on L-DOPA-induced motor complications in 6-hydroxydopamine-lesioned rats.” Hirosaki Daigaku Igakubu Hirosaki-shi 2001, 53 (1), 17-25, translated.
Online “http://www.pdpipeline.org/clinicaltrials/terminated—thearpy—thru2004.htm” accessed Aug. 30, 2010.
Goetz et. al. “Sarizotan as a Treatment for Dyskinesias in Parkinson's Disease: A Double-Blind Placebo-Controlled Trial” Movement Disorders, 2007, vol. 22, No. 2, pp. 179-186.
Chemical abstracts “Sarizotan” REGISTRY#: 351862-32-3 entry. 2001.
PubMed ID: 7857027 1994.
Overall K L, “Animal Behavior Case of the Month,” Journal of the American Veterinary Medical Association, XX, XX, Sep. 1, 1994, pp. 694-696, vol. 5, No. 205, XP008001693, ISSN: 0003-1488, cited in the application, p. 495, right-hand column, paragraphs 2,3.
Griebel G. et al., “5-HT1A Agonists Modulate Mouse Antipredator Defensive Behavior Differently from the 5-HT2A Antagonist Pirenperone,” Pharmacol. Biochem. Behav., 1995, pp. 235-244, vol. 51, No. 2-3, XP002197804, cited in the application, p. 242, p. 241, right-hand column, paragraph 1—paragraph 3, p. 241, left-hand column, last paragraph, p. 236, left-hand column, paragraph 2.
Bartoszyk G D et al., “Pharmacological Profile of EMD 128130: A Putative Atypical Antipsychotic with Dopamine D2 Antagonistic and Serotonin 5-HT1A Angonistic Properties,” Society for Neuroscience Abstracts, Oct. 28, 1997, p. 530, vol. 23, No. 1/2, XP001066595, ISSN: 0190-5295, abstract 207.5, Society for Neuroscience, US.
Schlemmer R F et al., “Antagonism of Amphetamine-induced Behavior by the Antipshychotic Candidate EMD 77697 in a Primate Social Colony Model for Screening Antipsychotic Agents,” Society for Neuroscience Abstracts, Oct. 25, 1997, p. 1931, vol. 23, No. 1/2, XP001066577, ISSN: 0190-5295, abstract 747.18, Society for Neuroscience, US.
Vliet Van B J et al, “Predinical Pharmacology of SLV301, a Potent Dopamine D2 Receptor Antagonist and Selective Serotonin Reuptake Inhibitor,” Society for Neuroscience Abstracts, Nov. 4-9, 2000, p. 87116, vol. 26, No. 1/2, XP008001595, ISSN: 0190-5295, abstract, Society for Neuroscience, US.
Liu Y et al., “Derivatives of CIS-2-amino-8-hyroxy-1-Methyltetralin: Mixed 5-HT1A-Receptor Agonists and Dopamine D2-receptor Antagonists,” Journal of Medicinal Chemistry, 1995, pp. 150-160, vol. 1, No. 38, XP001064450, ISSN: 0022-2623, the whole document, American Chemical society.
Joechle W, Fehlverhalten Und Anpassungsprobleme Bei Hund Und Katze Und Deren Pharmakologische Beeinflussbarkeit//Abnormal Behavior and Adaptation Problems and their Pharmacological Control in Dogs and Cats, Tieraerztliche Praxis, Nov. 1998, pp. 410-421, vol. 6, No. 26, XP008001694, ISSN: 0303-6286, the whole document.
Database Biosis (Online), Biosciences Information Service, STN AN= 1995:131485, XP002197805, Abstract Philadelphia, PA, US; & Molewijk et al., “Conditioned ultrasonic distress vocalizations in adult male rats as a behavioral paradigm for screening antipanic drugs,” Psychopharmacology, 1995, pp. 32-40, vol. 117, No. 1, abstract.
Database Drugnl (Online), STN AN=97:3859, XP002197806, abstract & R&D Focus Drug News, Mar. 11, 1997, abstract.
Rosengarten et al., Progress Neuro-psychopharmacol & Biological Psychiatry 30 (2006), The Effect of Chronic Adminstration of Sarizotan, 5-HT1Agonist/D3/4 Ligand on Haloperidol Induced Repetitive Jaw Movements in Rat Model of Tardive Dyskinesia, pp. 273-279.
Bara-Jimenez et al., Movement Disorders vol. 20, No. 8, 2005, Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease, pp. 932-936.
Kuenzel et al., Psychopharmacology © Springer-Verlag 2005—Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers, pp. 1-11.
Rabiner et al, Journal of Psychopharmacology—16(3) (2002)—Evaluation of EMD 128 130 occupancy of the 5-HT1Aand the D2receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride, pp. 195-199.
Olanow et al.,Clin Neuropharmacol—vol. 27, No. 2, Mar.-Apr. 2004, Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study), pp. 58-62.
Bartoszyk et al., J Neural Trans. (2004) 111: 113-126—Sarizotan, a serotonin 5-HT1Areceptor agonist and dopamine receptor ligand. 1. Neurochemcial profile.
Lorenc-Koci et al., Neuropharmacology 45 (2003)—Contribution of the serotonin 5-HT1Areceptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats, pp. 1057-1069.
Banoezyk et al., Soc. Neurosci. Abstr., vol. 23, Part 1, 1997—209.5 Pharmacological Profile of EMD 128130: A Putative Atypical Antipsychotic With Dopamine D2Antagonistic and Serotonin 5-HT1AAgonistic Properties, p. 530.
Bottcher et al., Soc. Neurosci. Abstr., vol. 22, Part 2, 1996, 234.1—SAR for Novel Chromanes: Atypical Neuroleptics with 5HT1A Agonistic and D2 Antagonistic Activity, p. 841.
Bibbiani et al., Neurology 57 Nov. (2 of 2) 2001—Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models, pp. 1829-1834.
Kleven M et al, “Role of 5-HT1A Receptors in the Ability of Mixed 5-HT1A Receptor Agonist/Dopamine D2 Receptor Antagonists to Inhibit Methylphe
Bartoszyk Gerd
Russ Herman
Seyfried Christoph
Weber Frank
Andres Janet L
Merck Patent GmbH
Millen White Zelano & Branigan P.C.
O'Dell David K
LandOfFree
Use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2716907